Safety of Tdap vaccine in pregnant women: an observational study -

Safety of Tdap vaccine in pregnant women: an observational study
Information type: Other primary research
Source: BMJ Open
Specialities: Family planning | Vaccination
Summary
This New Zealand based prospective observational study (over 4 weeks) of 793 women who received the acellular pertussis vaccine reported 115 adverse events, with 31 classified as serious (but not linked to the vaccine) eg obstetric bleeding, hypertension, preterm labour.
UKMi comment
In the UK, pregnant women are offered a single 0.5 ml dose of dTaP/IPV vaccine. The vaccine should be offered to women in every pregnancy, and should be offered between gestational weeks 16 and 32 to maximise the likelihood that the baby will be protected from birth.
Related links: